Cecilia Soriano
Group President, Infusion Therapies & Technologies And Pharmaceuticals
Baxter International Inc · BAX
$2.7M
Reported total · FY2025 · SCT Total as filed
Source: DEF 14A filed March 23, 2026. Prior years are from that filing's three-year table.
Catalog as of September 15, 2026. Not a live market feed.
- Salary
- $668K
- Stock Awards
- $1.3M
- Option Awards
- $253K
- Incentives
- $367K
- Other
- $66K
Compensation History
| Fiscal Year | Salary | Stock Awards | Total Compensation |
|---|---|---|---|
| 2025 | $668,247 | $1,300,147 | $2,654,841 |
Current Position
- Company
- Baxter International Inc
- Title
- Group President, Infusion Therapies & Technologies And Pharmaceuticals
- Ticker
- BAX · NYSE
- Fiscal Year
- 2025
SEC Sources
Fiscal years below are columns from the latest DEF 14A Summary Compensation Table (filed March 23, 2026), not separate historical filings.
| Fiscal Year | Source |
|---|---|
| 2025 | View SEC filing |
Accession 0001628280-26-020330.
Other Baxter International Executives
Andrew Hider
President and CEO
Baxter International · BAX
$29.8M
FY 2025 · DEF 14A
José E. Almeida
Former Chair Of The Board, President And Ceo
Baxter International · BAX
$7.7M
FY 2025 · DEF 14A
Brent Shafer
Baxter International · BAX
$3.8M
FY 2025 · DEF 14A
Joel Grade
Former Executive Vice President and CFO
Baxter International · BAX
$8.2M
FY 2025 · DEF 14A
Heather Knight
Former Executive Vice President, Coo And Interim Group President, Medical Products & Therapies
Baxter International · BAX
$6.1M
FY 2025 · DEF 14A
Reazur Rasul
Executive Vice President And Group President, Healthcare Systems & Technologies
Baxter International · BAX
$5.2M
FY 2025 · DEF 14A
David Rosenbloom
Executive Vice President And General Counsel
Baxter International · BAX
$3.8M
FY 2025 · DEF 14A
Alok Sonig
Former Executive Vice President And Group President, Pharmaceuticals
Baxter International · BAX
$5.2M
FY 2025 · DEF 14A